VEGFA and neoplasm: Hypoxia triggered by anti-VEGF therapy increases galectin-1 expression in tumor cells, where it binds glycosylated VEGFR2 on endothelial cells to sustain angiogenesis through VEGFA-mimetic signaling (Croci et al., 2014).